Alpha Teknova Q1 revenue rises, beats estimates

Alpha Teknova

06/05/2026 21:10

Overview

U.S. reagents producer's Q1 2026 revenue grew 13%, beating analyst expectations

Company reaffirmed 2026 revenue guidance of $42-44 mln

Gross margin improved to 34.2% from 30.7%, driven by higher revenue

Outlook

Alpha Teknova reaffirms 2026 revenue guidance of $42-44 mln

Company expects 2026 Free Cash Outflow of less than $10 mln

Company says improved market backdrop positions it for above-market growth

Result Drivers

CLINICAL SOLUTIONS GROWTH - Clinical Solutions revenue rose 85% year-on-year, supporting overall revenue growth

HIGHER SALES AND MARKETING SPEND - Operating expenses increased due to higher sales and marketing costs from increased headcount and marketing activities

INVESTMENTS AND MARKET BACKDROP - Management said past investments and an improved market backdrop position the company for above-market growth

Company press release: ID:nGNX7Wr0Rw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$11.08 mln
$10.21 mln (6 Analysts)
Q1 EPS
-$0.08
Q1 Net Income
-$4.56 mln
Q1 Gross Profit
$3.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Alpha Teknova Inc is $8.00, about 113.9% above its May 5 closing price of $3.74

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)